Title : Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.

Pub. Date : 2017 Aug 15

PMID : 28903416






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFkappaB, HIF-2alpha and VEGF expression. Sunitinib AKT serine/threonine kinase 1 Homo sapiens